摘要
目的研究肝细胞癌(hepatic cellular carcinoma,HCC)组织中GP73的表达变化,初步探讨其临床价值。方法免疫组化SP法检测100例HCC、10例肝胆管细胞癌(cholangiocellular carcinoma,CCC)、10例肝血管瘤、10例乳腺癌、10例直肠癌、10例肺小细胞性肺癌、10例胃黏液细胞癌及30例正常肝脏组织中GP73蛋白的表达,同时检测其中GP73表达阳性的20例HCC的癌旁组织及其周围正常组织。结果 GP73在HCC组织中阳性率(85%)明显高于其他各组织;GP73在HCC组织中表达的阳性率较其癌旁组织、正常组织明显升高并有统计学意义(P均<0.05);GP73的表达与HCC患者是否合并有腹水、肝硬化、淋巴结转移及门静脉分支侵犯有关。结论 GP73是HCC的肿瘤标记物之一,参与HCC的发生发展,可用于HCC的临床诊断。
Objective To investigate the expression of GP73 in hepatocellular carcinoma （ HCC ） tissues, and to explore its clinic significance. Methods The expression of GP73 in 100 HCC, 10CCC, 10 hemagioma, 10 rectal cancer, 10 breast cancer, 10 small cell lung cancer, 10 gastic mucinous adenocarcinoma were assessed by immunohistochemistry, the same method to assess 20 HCC, tumoradjacent specimens and its nomormal liver specimens. Results The positive ratio of GP73 （ 85% ） were significantly higher in patients with HCC compared to other diseases （ P 〈 0.05, respectively ）, the expression levels of GP73 was significantly higher in HCC than in tumor-adjacent tissue and normal liver tissue. GP73 expression was significantly related to tumor metastasis, vessel invasion （ P 〈 0.05 respectively ）. Conclusion GP73 may be used as a marker for diagnosis of HCC.
出处
《中国现代医生》
2011年第30期35-36,161,共2页
China Modern Doctor
